Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Orexigen Begins Slow Climb Up Slippery Slope Of Obesity Drug Sales

Executive Summary

Orexigen has a tough climb ahead as it sets out without a US partner to boost sales for its obesity drug Contrave with the goal of profitability by 2019, but it appears that doctors, patients and payers are becoming more open to pharmaceutical treatment.


Related Content

UK’s NICE Rejects Use Of Orexigen’s Mysimba For Obesity
Contrave Rxs Jump In Q1, But TV Commercial Runs Afoul Of FDA
Contrave Launch Raises Hopes For Korean Obesity Market Growth
Obesity Market Snapshot: Marketing Partners Giving Obesity The Slow Goodbye
Third Time's The Charm? Orexigen Terminates CONVENE
Orexigen Insists It Can Grow Contrave After Takeda Exit
Not A Total Fail For Orexigen
Orexigen conquers French objections to obesity drug with EU approval
Orexigen soars on CV data that FDA didn't want released


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts